Skip to content
Back to Investors
Trinity Capital

Trinity Capital

Venture Capital

Trinity Capital is an international alternative asset manager providing debt solutions to growth-oriented companies.

Portfolio

2

companies

Investment by month

By category

  • AI/ML£197M
  • MedTech£154M

By location

  • London£197M
  • Cambridge£154M

Portfolio companies

CS

CMR Surgical

CMR Surgical manufactures the Versius system for robotic minimal access surgery.

Dwelly

Dwelly

Dwelly acquires British letting agencies and automates their operations through artificial intelligence.


Team

Rob Lake

Rob Lake

Senior Managing Director, Life Sciences

Rob brings specialty finance and life sciences experience, currently serving as Group Head and Senior Managing Director at Trinity Capital. He previously held leadership roles at Runway Growth Capital, Western Alliance Bank, and Oxford Finance.

LinkedIn

Recent investments

Series B
$170M

EQT Growth and General Catalyst led the Series B financing, which includes equity and debt facilities to support further agency acquisitions.

"Dwelly is AI-first by default: we assume AI should be able to do every operational task. That changes what a lettings agent can be. AI takes over the transactional layer, while our people become world-class advisors to landlords and tenants"
— Ilya Drozdov, Co-founder and CEO
Growth
£69.0M

General Catalyst led the equity portion of the £69m investment, which also features a debt facility from Trinity Capital.

"We have crossed 10,000 properties under management, placing Dwelly among the UK’s top 15 largest letting agencies in less than 2 years – an unseen speed of growth for letting agencies. Our vision is to build an end-to-end platform evolving into a fully transactional rental marketplace with a robust fintech layer for rent collection and ancillary products."
— Ilya Drozdov, Co-founder and CEO
£154M

The financing round was backed by existing major investors and new participant Trinity Capital.

"CMR is a competitive, well-established company with a transformative product providing clear clinical value. We are now at a pivotal stage, poised to capitalise on significant opportunities for market expansion, including in the U.S., while continuing to penetrate deeper into existing markets. I would like to give thanks to our CFO, Andre Nel, and the team for securing this financing to provide the foundation for realising our strategic vision of making robotic assisted surgery accessible to all patients who need it whilst accelerating future product development."
— Massimiliano Colella, Chief Executive Officer